Camilla Sandberg
Chief Executive Officer chez MIRIS HOLDING AB
Profil
Camilla Myhre Sandberg is currently the Chief Executive Officer at Miris Holding AB since 2016.
She is also an Independent Director at Monivent AB and NextCell Pharma AB.
Previously, she worked as the Vice President-Sales & Marketing at BioLamina AB.
Ms. Sandberg completed her undergraduate degree in 1996 and MBA in 1998 from the University of Oslo.
Postes actifs de Camilla Sandberg
| Sociétés | Poste | Début |
|---|---|---|
| MIRIS HOLDING AB | Chief Executive Officer | 04/10/2016 |
| NEXTCELL PHARMA AB | Director/Board Member | 01/01/2017 |
| MONIVENT AB | Director/Board Member | - |
Anciens postes connus de Camilla Sandberg
| Sociétés | Poste | Fin |
|---|---|---|
BioLamina AB
 BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden. | Sales & Marketing | - |
Formation de Camilla Sandberg
| University of Oslo | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MIRIS HOLDING AB | Electronic Technology |
| MONIVENT AB | Health Technology |
| NEXTCELL PHARMA AB | Health Technology |
| Entreprise privées | 1 |
|---|---|
BioLamina AB
BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden. | Health Technology |
